After an almost 15-year absence, Roche's licensing deal for POL7080 from Polyphor Ltd. marks the pharma's return to antibiotics with a focus on multi-drug resistant pathogens.

The pharma believes narrow-spectrum or pathogen-specific activity - once viewed as a poor characteristic for antibiotic drug candidates - is the future of antibiotic development for two reasons.